Efficacy of Cashew Nut Protein Immunotherapy

Inclusion Criteria: * age between 4 and 17 years, * IgE (immunoglobulin E) -mediated cashew allergy confirmed with positive skin prick tests with cashew allergens (diameter of the wheal greater than 3mm) and/or specific IgE (immunoglobulin E) level greater than 0.35-kilo units of Allergen per liter (kUA/l), * allergic reaction to cashew protein during oral food challenge (OFC), * Signed Informed Consent by parent/legal guardian and patient aged \>16 years old, * Patient's and caregivers' cooperation with the researcher. Exclusion Criteria: * no confirmed allergy to cashew, * negative provocation test with cashew, * severe asthma, * mild/moderate asthma poorly controlled: FEV1 (forced expiratory volume at one second) \<80% (less than 5 perc), FEV1/FVC (forced expiratory volume at one second/forced vital capacity) \<75% (less than 5 perc), hospitalization for asthma exacerbation in the past 12 months, * oral/sublingual/subcutaneous immunotherapy to other allergens during the study, * eosinophilic gastroenteritis, * chronic diseases requiring ongoing treatment, including heart disease, epilepsy, metabolic diseases, diabetes, * taking medications: * oral, daily steroid therapy \>1 month in the past 12 months, * a minimum of 2 times oral steroid therapy (a period of at least 7 days) in the past 12 months, * one-time oral steroid therapy (min. 7 days) in the last 3 months, * biological treatment, * need to take antihistamines continuously, * therapy with β-blockers, ACE-inhibitors (angiotensin converting enzyme), calcium channel inhibitors, * pregnancy, * lack of consent to participate in the study, * lack of patient cooperation.